Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany.
The company is developing highly innovative immunotherapies to target various forms and stages of cancer.
Medigene concentrates on the development of personalized T cell-based therapies with the focus on T cell-receptor modified T cells (TCR-Ts) and has associated projects currently in pre-clinical and clinical development.
For more information, please visit http://medigene.com
Medigene’s TCR-T pipeline is being built to contain a collection of TCR-Ts that recognize different antigens which are expressed by various types of tumor.
Upon completion, Medigene’s TCR-T pipeline will enable individuals of diverse patient populations to be matched for the treatment with TCR-Ts according to their MHC molecules and specificities for antigens expressed by tumor cells.
The pipeline is built by natural TCR-Ts with optimal affinities that can be expressed in CD4+ or CD8+ cells, selected by their specificities.
Medigene's DC vaccines: The scientific team of Medigene has developed new, fast and efficient methods for generating autologous (patient-specific) mature dendritic cells which have the relevant characteristics to generate very strong T cell and NK cell immune responses.
The dendritic cells can be loaded with various tumor antigens to treat different forms of cancer.
Medigene is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The company concentrates on the development of personalized T cell-based immunotherapies.